AMG 386 + Paclitaxel + AMG 386 Placebo + Carboplatin
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Trial Timeline
Jan 1, 2012 → Dec 1, 2016
NCT ID
NCT01493505About AMG 386 + Paclitaxel + AMG 386 Placebo + Carboplatin
AMG 386 + Paclitaxel + AMG 386 Placebo + Carboplatin is a phase 3 stage product being developed by Amgen for Fallopian Tube Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01493505. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01493505 | Phase 3 | Terminated |
Competing Products
20 competing products in Fallopian Tube Cancer